You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 160 No. 7, July 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •HIV/AIDS
 •Treatment Adherence
 •Violence and Human Rights
 •Bioterrorism
 •Drug Therapy
 •Adherence
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Human Immunodeficiency Virus Prophylaxis for Sexual Assault Survivors

What We Need to Know

Arch Pediatr Adolesc Med. 2006;160:754-755.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A dolescent sexual assault is unfortunately all too common. An analysis of the 2001 Youth Risk Behavior Survey revealed that 10.2% of women and 5.1% of men reported forced sexual intercourse at least once in their lifetimes.1 Recent National Criminal Victimization Survey results revealed that annually 1/10 of one percent of all individuals aged 12 or older had survived rape or sexual assault.2 The ratio of male-female survivors is 1:10, and 29% of victims are 12 to 17 years old.

There is a general concern that survivors are at increased risk for acquiring human immunodeficiency virus (HIV) infection via the sexual assaults. Most reviews cite a case report by Murphy et al,3 which describes HIV seroconversion related to rape. Epidemiological studies of consensual coitus have shown that the risk for heterosexual sexual transmission from 1 coital act ranges from 0.001 to 0.008.4 Estimates vary by the stage of the infected . . . [Full Text of this Article]

AUTHOR INFORMATION

Jonathan M. Ellen, MD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED ARTICLE

Use of Human Immunodeficiency Virus Postexposure Prophylaxis in Adolescent Sexual Assault Victims
Elyse Olshen, Katherine Hsu, Elizabeth R. Woods, Marvin Harper, Brooke Harnisch, and Cathryn L. Samples
Arch Pediatr Adolesc Med. 2006;160(7):674-680.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.